GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (LTS:0HA3) » Definitions » Shiller PE Ratio

Adverum Biotechnologies (LTS:0HA3) Shiller PE Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Adverum Biotechnologies Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Adverum Biotechnologies Shiller PE Ratio Historical Data

The historical data trend for Adverum Biotechnologies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Shiller PE Ratio Chart

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adverum Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adverum Biotechnologies's Shiller PE Ratio

For the Biotechnology subindustry, Adverum Biotechnologies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adverum Biotechnologies's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Shiller PE Ratio falls into.



Adverum Biotechnologies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Adverum Biotechnologies's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Adverum Biotechnologies's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.5/131.7762*131.7762
=-1.500

Current CPI (Mar. 2024) = 131.7762.

Adverum Biotechnologies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -4.007 100.560 -5.251
201409 -5.000 100.428 -6.561
201412 -4.567 99.070 -6.075
201503 -3.800 99.621 -5.027
201506 -3.800 100.684 -4.973
201509 -5.500 100.392 -7.219
201512 -5.450 99.792 -7.197
201603 -5.700 100.470 -7.476
201606 -17.600 101.688 -22.808
201609 -3.500 101.861 -4.528
201612 -5.400 101.863 -6.986
201703 -3.800 102.862 -4.868
201706 -2.700 103.349 -3.443
201709 -3.200 104.136 -4.049
201712 -3.200 104.011 -4.054
201803 -3.000 105.290 -3.755
201806 -3.000 106.317 -3.718
201809 -3.400 106.507 -4.207
201812 -2.400 105.998 -2.984
201903 -2.300 107.251 -2.826
201906 -2.300 108.070 -2.805
201909 -2.500 108.329 -3.041
201912 -3.000 108.420 -3.646
202003 -3.100 108.902 -3.751
202006 -3.600 108.767 -4.362
202009 -3.100 109.815 -3.720
202012 -3.900 109.897 -4.676
202103 -2.900 111.754 -3.420
202106 -4.500 114.631 -5.173
202109 -3.900 115.734 -4.441
202112 -3.500 117.630 -3.921
202203 -3.800 121.301 -4.128
202206 -4.400 125.017 -4.638
202209 -4.000 125.227 -4.209
202212 -3.300 125.222 -3.473
202303 -2.900 127.348 -3.001
202306 -3.100 128.729 -3.173
202309 -3.300 129.860 -3.349
202312 -2.300 129.419 -2.342
202403 -1.500 131.776 -1.500

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adverum Biotechnologies  (LTS:0HA3) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Adverum Biotechnologies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (LTS:0HA3) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (LTS:0HA3) Headlines

No Headlines